SmartTarget announces product launch

London, 30th September 2016

SmartTarget Ltd announces the launch of its new device for the detection of prostate cancer. The CE certified SmartTarget system is an image fusion device for guiding targeted, transperineal prostate biopsy.

Designed and developed by world leading urologists and biomedical engineers, the technology enables image-directed tumour targeting during minimally invasive biopsy procedures for prostate cancer patients and has undergone extensive clinical evaluation in over 200 patients at UCLH.

Users of the SmartTarget software benefit from an interface that is intuitive and easy-to-use. Patented, state-of-the-art image fusion techniques allow for a simple and efficient single-user workflow in which changes in the shape and position of the prostate between magnetic resonance (MR) and ultrasound images are automatically compensated for.

Recently demonstrated at the British Association of Urological Surgeons’ annual scientific meeting, the market-ready SmartTarget generated an enthusiastic response from visitors.

CEO Mark Kirby said: “I am very excited to be leading SmartTarget as we commercialise the SmartTarget prostate fusion biopsy system. There are significant changes coming in the care pathway for men with prostate cancer and I believe that SmartTarget is ideally placed to deliver this better and more economic pathway.”

Chief Scientific Officer and co-inventor of the SmartTarget software Dr Dean Barratt commented: “The SmartTarget software is the culmination of 10 years’ research, and incorporates some of the most advanced technology available in any commercial medical image fusion system. I am delighted that this technology is now able to become widely available to benefit patients across the UK and Europe, and look forward to continuing to develop the software for new medical applications.”

Development of the device was supported by funding from the Health Innovation Challenge Fund, a parallel funding partnership between the UK Department of Health and the Wellcome Trust, enabling the company to offer a product that is affordable for both the public and private healthcare sectors. The research was also part-funded by the National Institute for Health Research (NIHR) University College London Hospital Biomedical Research Centre (BRC)

About SmartTarget Ltd.

A spinout of UCL (University College London) and UCLB, SmartTarget is dedicated to providing high accuracy, easy-to-use and affordable medical image fusion solutions for guiding prostate cancer biopsy and minimally-invasive cancer treatments. Its unique technology is based on research by scientists and engineers within UCL’s Centre for Medical Image Computing (CMIC), one of the world’s leading academic groups in the field of medical image processing and analysis.
See www.smarttarget.co.uk for further information.

Contact:-

Mark Kirby
CEO
SmartTarget Ltd
mark.kirby@smarttarget.co.uk
+44 (0)207 993 2390

SmartTarget is a registered trademark of SmartTarget Ltd.